trending Market Intelligence /marketintelligence/en/news-insights/trending/U-OGUzLg0v4hOHpp9onQlQ2 content esgSubNav
In This List

ContraVir Pharmaceuticals fails to regain Nasdaq compliance

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022


ContraVir Pharmaceuticals fails to regain Nasdaq compliance

The Nasdaq Stock Market LLC notified ContraVir Pharmaceuticals Inc. that it had not regained compliance with the exchange's minimum bid listing requirement of $1 per share.

The exchange further said that ContraVir was not eligible for a second 180-day period since it did not comply with the minimum $5 million stockholders' equity initial listing requirement for The Nasdaq Capital Market.

ContraVir has requested a hearing before the Nasdaq Hearings Panel, staying the delisting process. The panel has the discretion to grant the company an extension through no later than June 2, 2018.